GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » EBIT

NeuroMetrix (NeuroMetrix) EBIT : $-7.15 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix EBIT?

NeuroMetrix's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NeuroMetrix's annualized ROC % for the quarter that ended in Dec. 2023 was -267.77%. NeuroMetrix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -308.28%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NeuroMetrix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 79.49%.


NeuroMetrix EBIT Historical Data

The historical data trend for NeuroMetrix's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix EBIT Chart

NeuroMetrix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.54 -2.10 -2.29 -4.74 -7.15

NeuroMetrix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 -1.71 -1.62 -1.96 -1.86

Competitive Comparison of NeuroMetrix's EBIT

For the Medical Devices subindustry, NeuroMetrix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroMetrix's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's EV-to-EBIT falls into.



NeuroMetrix EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroMetrix  (NAS:NURO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NeuroMetrix's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-7.428 * ( 1 - 0% )/( (2.867 + 2.681)/ 2 )
=-7.428/2.774
=-267.77 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

NeuroMetrix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.428/( ( (0.555 + max(1.956, 0)) + (0.544 + max(1.764, 0)) )/ 2 )
=-7.428/( ( 2.511 + 2.308 )/ 2 )
=-7.428/2.4095
=-308.28 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.614 + 1.667 + 0.787) - (0.782 + 0 + 0.33)
=1.956

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.519 + 1.559 + 0.779) - (0.746 + 0 + 0.347)
=1.764

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NeuroMetrix's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-7.151/-8.996
=79.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroMetrix EBIT Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroMetrix (NeuroMetrix) Business Description

Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
Bradley M Fluegel director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins officer: Chief Financial Officer
Topline Capital Management, Llc other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp 10 percent owner 544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani director, officer: Chairman, President and CEO C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin officer: Senior VP, Consumer C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van director C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran officer: S. VP and GM, International C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc officer: Senior Vice President & GM
Walter Christensen officer: Sr. VP, Global Sales C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor director 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C) 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017